Eysuvis Now Available For Dry Eye Disease
Eysuvis (loteprednol etabonate ophthalmic suspension) is now available for the short-term treatment of the signs and symptoms of dry eye disease.
Eysuvis (loteprednol etabonate ophthalmic suspension) is now available for the short-term treatment of the signs and symptoms of dry eye disease.
Over-the-counter (OTC) and prescription agents for the management of dry eye.
This week we cover a study that identified factors associated with strong antibody responses to COVID; How convalescent plasmas benefits may be limited; A nasal spray to treat diabetic gastroparesis; Recommendations for colorectal cancer screening; And a new treatment approved for dry eye disease. And of course, movie trivia!
Results from 4 clinical trials showed that treatment with Eysuvis was associated with significant improvements in both the signs and symptoms of dry eye disease.
The FDA has accepted for review the New Drug Application for Eysuvis™ (loteprednol etabonate ophthalmic suspension; Kala Pharmaceuticals) 0.25% for the treatment of dry eye disease.
Positive topline data were announced from the phase 3 ONSET-2 study of OC-01 (varenicline; Oyster Point Pharma) nasal spray for the treatment of the signs and symptoms of dry eye disease.
Allergan has announced the addition of 3 new over-the-counter artificial tear products to their Refresh line.
The NDA includes data from one Phase 2 and two Phase 3 clinical trials (STRIDE 1 and STRIDE 2) involving ~2000 individuals with dry eye disease.
Cequa was evaluated in 2 multicenter, randomized studies involving 1,048 patients with dry eye disease.
The new ocular drops contain carboxymethylcellulose (CMC) 0.5%, hyaluronic acid (HA), glycerin 0.9%, and other organic osmoprotectants.